TOP2A and pulmonary arterial hypertension: And ten hub genes, including HSP90AA1, CDC5L, MDM2, LRRK2, CFTR, IQGAP1, CAND1, TOP2A, DDX21, and HIF1A may be new therapeutic targets for patients with PAH to be further validated.